{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045998","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.817047+00:00","generated_at":"2026-05-30T03:33:19.789093+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"VYNE reports Q3 net loss $12.2M; VYN201 Phase 2b enrollment exceeds target, top-line mid-2025","bullets":["Net loss of $12.2M ($0.29/sh) in Q3 2024 vs $6.6M ($2.01/sh) in Q3 2023, driven by higher R&D spend.","Cash and marketable securities of $70.2M; expected to fund operations through end of 2025.","VYN201 Phase 2b vitiligo trial enrollment exceeded target; fully enrolled Dec 2024, top-line mid-2025.","VYN202 Phase 1a SAD data positive; MAD data expected Q4 2024. Plans for Phase 1b in psoriasis and RA.","R&D expenses rose 208.9% to $10.2M due to advancing clinical trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045998","json":"https://secwatch.observer/filing/0001628280-24-045998.json","markdown":"https://secwatch.observer/filing/0001628280-24-045998.md","text":"https://secwatch.observer/filing/0001628280-24-045998.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000162828024045998/0001628280-24-045998-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000162828024045998/mnlo-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:33:19.789093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}